ERBB2 and inflammatory breast carcinoma: A slightly lower, but still comparable response rate of 36% was found in a study, which also focused on adjacent DCIS in HER2-positive IBC, in which patients were treated with taxane-based chemotherapy plus trastuzumab and also pertuzumab in a small subgroup [25].